Differential effect of IL‐15 and IL‐2 on survival of phytohemagglutinin‐activated umbilical cord blood T cells

Cytokine immunotherapy using interleukin (IL)‐2 and IL‐15 may be beneficial for patients receiving umbilical cord blood (CB) transplantation by ameliorating post‐transplant T‐cell apoptosis. The present study compares the differential effect of IL‐15 and IL‐2 on survival of phytohemagglutinin (PHA)‐...

Full description

Saved in:
Bibliographic Details
Published inAmerican journal of hematology Vol. 80; no. 2; pp. 106 - 112
Main Authors Lin, Syh‐Jae, Cheng, Po‐Jen, Hsiao, Shiu‐Shan, Lin, Hui‐Hao, Hung, Pei‐Fen, Kuo, Ming‐Ling
Format Journal Article
LanguageEnglish
Published Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.10.2005
Wiley-Liss
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Cytokine immunotherapy using interleukin (IL)‐2 and IL‐15 may be beneficial for patients receiving umbilical cord blood (CB) transplantation by ameliorating post‐transplant T‐cell apoptosis. The present study compares the differential effect of IL‐15 and IL‐2 on survival of phytohemagglutinin (PHA)‐activated CB and adult peripheral blood (APB) T lymphocytes. In comparison with IL‐2, IL‐15 preferentially enhanced the survival of CB PHA‐activated T cells by decreasing the caspase‐3+ population and by increasing the Bcl‐2+ population. Activated CB T cells were more susceptible to TNF‐α‐induced apoptosis compared to their adult counterparts. However, the susceptibility could be abrogated by IL‐15 but not by IL‐2. IL‐15 but not IL‐2 down‐regulated CD28 expression on both activated CB and APB CD8+ T cells, with a much greater effect seen with CB. Western‐blot analysis shows that IL‐15 Rα is deficient in CB compared to APB immediately after PHA stimulation, while culturing with IL‐15 significantly enhanced CB IL‐15 Rα expression to levels comparable to that of adults. Thus, IL‐15 may provide a better therapeutic choice for immune reconstitution than IL‐2 post‐CB transplantation due to its preferential survival enhancing effect on CB T cells. Am. J. Hematol. 80:106–112, 2005. © 2005 Wiley‐Liss, Inc.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0361-8609
1096-8652
DOI:10.1002/ajh.20431